Trial Profile
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Ciclosporin (Primary) ; Eltrombopag (Primary)
- Indications Anaemia; Aplastic anaemia; Neutropenia; Pancytopenia; Thrombocytopenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- 22 Mar 2023 Planned End Date changed from 30 Jan 2024 to 30 Jan 2029.
- 15 Sep 2021 Results (n=178) of update on long-term outcomes in patients treated with IST and EPAG on a prospective phase 2 trial, with largest cohort and longest follow-up to date published in the Blood.
- 29 Jun 2020 Status changed from active, no longer recruiting to recruiting.